Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

Review of tesamorelin, an FDA-approved GHRH analog (2010), for treating HIV-associated lipodystrophy, evaluating efficacy and safety from published literature.

Abstract

To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection.. Literature was obtained through MEDLINE (1948-November 2011) and International Pharmaceutical Abstracts (1970-October 2011) using the search terms tesamorelin, TH9507, growth.

Hallazgos Clave

Additional publications were obtained through review of references within primary literature publications as well as pertinent Web sites. | All articles published in English identified from the data sources were evaluated and all pertinent information was included. | All studies relevan

Diseño del Estudio

Review article